Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B known ✓ | Q13224 | 4/20 | 0.71 |
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.65 |
| ▸ | BCHE known ✓ | P06276 | 4/20 | 0.65 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.78 |
| ▸ | BACE1 | P56817 | 6/20 | 0.65 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.60 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663239 | 0.98 | GRIN2B (0.74) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL30509625 | 0.91 | GRIN2B (0.67) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Methyl Alcohol SCHEMBL27513196 | 0.91 | GRIN2B (0.67) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL11785266 | 0.91 | GRIN2B (0.67) | MEN1KMT2ARAB9AGRIN2BACHE | |
| SCHEMBL3184557 | 0.91 | GRIN2B (0.67) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL27637041 | 0.90 | MEN1 (0.66) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL5244788 | 0.90 | MEN1 (0.66) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL21777023 | 0.90 | GRIN2B (0.65) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL11782513 | 0.90 | HRH3 (0.69) | MEN1KMT2ARAB9AGRIN2BACHE | |
| Hydrochloric Acid SCHEMBL11781778 | 0.90 | HRH3 (0.69) | MEN1KMT2ARAB9AGRIN2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-109384729-B | Pyrimidinedione compounds for cardiac disorders | 迈奥卡迪亚公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-112533903-B | Benzimidazole derivatives and their use as IDH1 inhibitors | 昆药集团股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3683222-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-3135674-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| WO-2011123937-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7235664-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| CN-1948266-A | Method of preparing N-mono substituted benzylamine by catalytic hydrogenation reduction amination | UNIV TSINGHUA (CN) | 2007-04-18 | — | — | CN | disclosed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6903216-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| US-20030187033-A1 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | KCNJ2, KCNQ5, KCNH1 | GRIN2B 3243/4885ACHE 1556/4885BCHE 4592/4885 |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | CBR3, CBR1, CYCS | GRIN2B 1083/4885ACHE 1559/4885BCHE 1308/4885 |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | KCNH1, KCNH2, KCNJ2 | GRIN2B 2848/4885ACHE 1308/4885BCHE 3777/4885 |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | CBR3, CBR1, CYCS | GRIN2B 1210/4885ACHE 1472/4885BCHE 1219/4885 |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | KCNJ2, KCNQ5, KCNH1 | GRIN2B 2956/4885ACHE 1950/4885BCHE 4387/4885 |
| US-20030187033-A1 | Anthranilamides and methods of their use | KCNH1, KCNJ2, KCNH2 | GRIN2B 2683/4885ACHE 1605/4885BCHE 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.